Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Metformin in Alport Syndrome: A Randomized, Double-blind, Placebo-controlled Study in China

NCT05655728 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT05655728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05655728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Metformin in Alport Syndrome: A Randomized, Double-blind, Placebo-controlled Study in China
Lead sponsor
Peking University First Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
January 3, 2023
Completion date
April 20, 2025
Enrollment
78 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome, metformin